As a blockbuster heart failure drug by Swiss pharma giant Novartis (NOVN: VX) goes off-patent, several Indian drug majors are rushing to market with their generic applications. The patent loss of Entresto (sacubitril/valsartan) has brought on significant disruptions in India’s cardiology sector. High courtroom drama ensued a few days before the patent loss and had everyone on tenterhooks, reports The Pharma Letter’s India correspondent.
In India, Entresto is marketed as Vymada by Novartis, while the product's secondary brands Cidmus and Azmarda are marketed by local partners Lupin (BOM: 500257) and Cipla (BOM: 500087), respectively.
The drug is one of the fastest-growing drugs in the country's cardiovascular market. With a cardiac market valued at approximately $2.83 billion in India alone, Vymada reportedly reached $67.71 million sales in the Indian cardiac market. It is estimated to have a size of $4 billion globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze